Immunotherapy of glioblastoma: Recent advances and future prospects

Glioblastoma (GBM) stands out as the most common, aggressive form of primary malignant brain tumor conferring a devastatingly poor prognosis. Despite aggressive standard-of-care in surgical resection and chemoradiation with temozolomide, the median overall survival of patients still remains no longe...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Boyang, Wang, Guoqing, Tang, Xin, Tong, Aiping, Zhou, Liangxue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Immunotherapeutics – Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248956/
https://www.ncbi.nlm.nih.gov/pubmed/35344682
http://dx.doi.org/10.1080/21645515.2022.2055417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248956/
https://www.ncbi.nlm.nih.gov/pubmed/35344682
http://dx.doi.org/10.1080/21645515.2022.2055417

Ejemplares similares